Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midkine siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Midkine siRNA refers to a class of experimental small interfering RNA (siRNA) molecules designed to silence the expression of the midkine (MK) gene. Midkine is a heparin-binding growth factor that is frequently overexpressed in various malignant tumors and inflammatory conditions, where it promotes cell proliferation, migration, survival, and angiogenesis. By utilizing the RNA interference (RNAi) pathway, midkine siRNA induces the sequence-specific degradation of midkine mRNA, thereby reducing protein levels and inhibiting tumor progression. Preclinical research has explored the therapeutic potential of midkine siRNA in several indications, including oral squamous cell carcinoma, gastric cancer, neuroblastoma, osteosarcoma, and hepatocellular carcinoma, as well as vascular conditions such as intimal hyperplasia. No specific proprietary drug product or clinical-stage program under this exact name has been identified, and it is primarily used as a research tool to investigate midkine biology.
- Other names
- MK siRNAmidkine-mediated siRNA
02
Targets
MDK (Midkine)
Beyond the preview
Go deeper on midkine siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midkine siRNA.